A Small Molecule Polyamine Oxidase Inhibitor Blocks Androgen-Induced Oxidative Stress and Delays Prostate Cancer Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model

被引:31
作者
Basu, Hirak S. [2 ]
Thompson, Todd A. [2 ]
Church, Dawn R. [2 ]
Clower, Cynthia C. [2 ]
Mehraein-Ghomi, Farideh [2 ]
Amlong, Corey A. [2 ]
Martin, Christopher T. [2 ]
Woster, Patrick M. [1 ]
Lindstrom, Mary J. [2 ]
Wilding, George [2 ]
机构
[1] Wayne State Univ, Dept Pharmaceut Chem, Detroit, MI USA
[2] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA
关键词
CARCINOMA-CELLS; NUDE-MICE; ANTIOXIDANTS; ANALOGS; CARCINOGENESIS; DERIVATIVES; CATABOLISM; GROWTH; PATHOBIOLOGY; INDUCTION;
D O I
10.1158/0008-5472.CAN-08-2472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High levels of reactive oxygen species (ROS) present in human prostate epithelia are an important etiologic factor in prostate cancer (Cap) occurrence, recurrence, and progression. Androgen induces ROS production in the prostate by a yet unknown mechanism. Here, to the best of our knowledge, we report for the first time that androgen induces an overexpression of spermidine/spermine N1-acetyltransferase, the rate-limiting enzyme in the polyamine oxidation pathway. As prostatic epithelia produce a large excess of polyamines, the androgen-induced polyamine oxidation that produces H2O2 could be a major reason for the high ROS levels in the prostate epithelia. A small molecule polyamine oxidase inhibitor N,N'-butanedienyl butanediamine (MDL 72,527 or CPC-200) effectively blocks androgen-induced ROS production in human Cap cells, as well as significantly delays Cap progression and death in animals developing spontaneous Cap. These data show that polyamine oxidation is not only a major pathway for ROS production in prostate, but inhibiting this pathway also successfully delays Cap progression. [Cancer Res 2009;69(19):7689-95]
引用
收藏
页码:7689 / 7695
页数:7
相关论文
共 39 条
[1]  
BASU HS, 1993, CANCER RES, V53, P3948
[2]   N-2,3-BUTADIENYL-1,4-BUTANEDIAMINE DERIVATIVES - POTENT IRREVERSIBLE INACTIVATORS OF MAMMALIAN POLYAMINE OXIDASE [J].
BEY, P ;
BOLKENIUS, FN ;
SEILER, N ;
CASARA, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (01) :1-2
[3]   The role of polyamine catabolism in anti-tumour drug response [J].
Casero, RA ;
Wang, Y ;
Stewart, TM ;
Devereux, W ;
Hacker, A ;
Wang, Y ;
Smith, R ;
Woster, PM .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 :361-365
[4]   PROOXIDANT STATES AND TUMOR PROMOTION [J].
CERUTTI, PA .
SCIENCE, 1985, 227 (4685) :375-381
[5]   Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells [J].
Church, DR ;
Lee, E ;
Thompson, TA ;
Basu, HS ;
Ripple, MO ;
Ariazi, EA ;
Wilding, G .
PROSTATE, 2005, 63 (02) :155-168
[6]  
Cohen SS, 1998, GUIDE POLYAMINES, P296
[7]   LIPID-PEROXIDATION - A COMMON PATHOGENETIC MECHANISM [J].
DARGEL, R .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 1992, 44 (04) :169-181
[8]   HUMAN ANDROGEN RECEPTOR EXPRESSED IN HELA-CELLS ACTIVATES TRANSCRIPTION IN-VITRO [J].
DEVOS, P ;
SCHMITT, J ;
VERHOEVEN, G ;
STUNNENBERG, HG .
NUCLEIC ACIDS RESEARCH, 1994, 22 (07) :1161-1166
[9]  
FEIG DI, 1994, CANCER RES, V54, pS1890
[10]   A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice [J].
Frydman, B ;
Porter, CW ;
Maxuitenko, Y ;
Sarkar, A ;
Bhattacharya, S ;
Valasinas, A ;
Reddy, VK ;
Kisiel, N ;
Marton, LJ ;
Basu, HS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (06) :488-492